$Nevro (NVRO.US)$ Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients Thursday, 6th February at 9:30 am AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement fo...
$Nevro (NVRO.US)$Reuters 6 mins ago Nevro's Hfx Iq™ Spinal Cord Stimulation With AI Technology Receives Ce Mark Certification in Europe, Increasing Product Expansion Globally
$Nevro (NVRO.US)$ Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation Nevro Corp. (NYSE: NVRO) has announced the FDA approval and market release of HFX iQ™ with HFX AdaptivAI™, an AI-driven spinal cord stimulation (SCS) system for chronic pain management. This technology leverages insights from over 100,000 patients and more than 100 million data points to provide personalized, responsive pain relief in real time. Key features of HFX Adaptiv...
Trytosaveabit
Newbee4
OP
:
Thank you! I will say after the big drop if you’re interested in a swing trade? It may be a good place to scale in a little at a time to see if it hit bottom and in turn some may start buying thinking it’s a good place to get in at a bargain?
Newbee4
OP
Trytosaveabit
:
That was kinda what I was thinking. I just thought it was strange that it had no comment's. Thanks again and safe travels tomorrow
Nevro's low P/S ratio may be due to its poor revenue outlook. Shareholders accept this as they anticipate no future revenue surprises. These conditions could continue to limit the share price.
Nevro's growth strategy, prioritizing expansion over steady profits, is viewed as risky, leading to a rapidly declining share price. Despite insider purchases, the company's overall performance has been disappointing, resulting in an annual loss of 8% for shareholders over five years.
Insiders buying shares over the past year, including one at a price higher than current, signals positive views of the company's future. While no insider transactions happened in recent three months, activities over the year suggest firm belief in potential.
The disappointing performance of Nevro's stock may be due to low growth and profit rates. Despite insider purchases, market sentiment towards Nevro remains negative, possibly an overreaction.
Nevro Stock Forum
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
Thursday, 6th February at 9:30 am
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement fo...
6 mins ago
Nevro's Hfx Iq™ Spinal Cord Stimulation With AI Technology Receives Ce Mark Certification in Europe, Increasing Product Expansion Globally
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
Nevro Corp. (NYSE: NVRO) has announced the FDA approval and market release of HFX iQ™ with HFX AdaptivAI™, an AI-driven spinal cord stimulation (SCS) system for chronic pain management. This technology leverages insights from over 100,000 patients and more than 100 million data points to provide personalized, responsive pain relief in real time.
Key features of HFX Adaptiv...
No comment yet